LeMaitre Vascular: The Market Is Catching On To This Dividend Growth Story
Discover why LeMaitre's expansion in the peripheral vascular disease market and strong dividend growth make it an appealing ...
ETF Daily News8h
FY2024 EPS Estimate for LeMaitre Vascular Raised by Analyst
LeMaitre Vascular, Inc. (NASDAQ:LMAT – Free Report) – Stock analysts at Barrington Research upped their FY2024 earnings per ...
Lemaitre Vascular: Strong Buy Rating Supported by Robust Financials and Strategic Growth Initiatives
Lemaitre Vascular (LMAT – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Daniel ...
In-Depth Examination Of 4 Analyst Recommendations For LeMaitre Vascular
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $95.25, a high ...
Lemaitre Vascular: Strong Financial Performance and Positive Outlook Drive OUTPERFORM Rating
In a report released today, Michael Petusky from Barrington maintained a Buy rating on Lemaitre Vascular (LMAT – Research Report), with a ...
LeMaitre to Participate at Upcoming Investor Conferences in November
BURLINGTON, Mass., Nov. 01, 2024 (GLOBE NEWSWIRE) -- (Nasdaq:LMAT) announced today that management will be participating in ...
LeMaitre Vascular Third Quarter 2024 Earnings: Beats Expectations
Third Quarter 2024 Results Key Financial Results Revenue: US$54.8m (up 16% from ...
ETF Daily News3d
LeMaitre Vascular, Inc. (NASDAQ:LMAT) Receives Consensus Rating of “Moderate Buy” from Analysts
LeMaitre Vascular has a 52-week low of $45.96 and a 52-week high of $101.67. LeMaitre Vascular ( NASDAQ:LMAT – Get Free Report ) last issued its earnings results on Thursday, October 31st.
Investing4d
LeMaitre Vascular stock target upgraded, keeps buy rating on strong Q3 results
Friday saw an update from Stifel on LeMaitre Vascular (NASDAQ:LMAT) shares, with the firm raising the price target on the company's shares to $100 from $95, while maintaining a Buy rating.
Seeking Alpha5d
LeMaitre Vascular, Inc. (LMAT) Q3 2024 Earnings Call Transcript
Welcome to the LeMaitre Vascular Q3 2024 Financial Results Conference Call. As a reminder, today's call is being recorded. At this time, I would like to turn the call over to Mr. J.J. Pellegrino ...
Investing5d
LeMaitre Vascular earnings beat by $0.05, revenue topped estimates
LeMaitre Vascular sees FY 2024 EPS of $0.47-$0.51 versus the analyst consensus of $0.46. LeMaitre Vascular sees FY 2024 revenue of $54.90M-$56.90M versus the analyst consensus of $55.60M.